Fisher & Paykel Healthcare (ASX:FPH) - CEO & Managing Director, Lewis Gradon
CEO & Managing Director, Lewis Gradon
Source: Fisher & Paykel Healthcare
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Fisher & Paykel Healthcare (FPH) has provided revenue guidance for the financial year ending March 31, 2022
  • The Auckland-based healthcare company expects full year operating revenue for the 2022 financial year to be in the range of $1.675 billion to $1.70 billion
  • Despite supply chain constraints, the company’s Homecare product group sales of OSA masks is currently tracking above first half growth rate
  • The company intends to release its financial results for the year ending 31 March on May 25
  • Fisher & Paykel Healthcare shares were flat at $25.76

Fisher & Paykel Healthcare (FPH) has provided revenue guidance for the financial year ending March 31, 2022.

The Auckland-based healthcare company expects full year operating revenue for the 2022 financial year to be in the range of $1.675 billion to $1.7 billion.

With the uncertainty surrounding COVID-19, vaccinations and lockdowns when it released its full-year results in May last year, Fisher & Paykel did not provide guidance for FY22.

It said today despite supply chain constraints, the company’s Homecare product group sales of OSA masks is currently tracking above first half growth rate.

Freight rates remain elevated and for the 2022 financial year are expected to impact the company’s long-term gross margin target of 65 per cent by approximately 250 basis points.

The company intends to release its financial results for the year ending 31 March on May 25.

“Our second half hospital consumables revenue is currently tracking to be similar to … that we reported in the first half of the 2022 financial year. This is consistent with reports of the increasing prevalence of the Omicron variant over the last two months and its associated lower respiratory intervention requirements, as well as a relatively mild flu season in the northern hemisphere,” said Managing Director and Chief Executive Officer Lewis Gradon.

“Regardless of how COVID-19 effects unfold over the short term, we are confident our business is well-placed to contribute to a positive change in clinical practice and improving outcomes for respiratory patients in general over the long term.”

FPH specialises in design, manufacture and marketing of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnoea.

The company’s shares were unchanged at $25.76 at 9.56am AEDT.

FPH by the numbers
More From The Market Herald

" Flynn Gold (ASX:FG1) intersects high-grade gold from maiden Trafalgar drilling

Flynn Gold (ASX:FG1) has intersected up to 52.20g/t gold under the maiden drilling program at the…

" Bubs Australia (ASX:BUB) halts trade ahead of $63m equity raising

Bubs Australia (ASX:BUB) halts trade ahead of its underwritten $63 million capital raise to support the…
Cavalier Resources (ASX:CVR) - Executive Chairman, Ranko Matic

" Cavalier Resources (ASX:CVR) begins PFS at Crawford

Cavalier Resources (ASX:CVR) has begun a pre-feasibility study (PFS) at the Crawford Gold Project within the…